Overview

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis.

Status:
Not yet recruiting

Trial end date:
2025-05-08

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

AstraZeneca